CD19-CAR-T cells
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Malignancy
Conditions
B-cell Malignancy
Trial Timeline
Aug 1, 2019 → Mar 31, 2021
NCT ID
NCT03952923About CD19-CAR-T cells
CD19-CAR-T cells is a phase 1 stage product being developed by Avalon GloboCare for B-cell Malignancy. The current trial status is completed. This product is registered under clinical trial identifier NCT03952923. Target conditions include B-cell Malignancy.
What happened to similar drugs?
3 of 20 similar drugs in B-cell Malignancy were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03952923 | Phase 1 | Completed |
Competing Products
20 competing products in B-cell Malignancy